NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) — The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.  

AT&T Inc. (NYSE: T)
Class Period: (A) Shares purchased pursuant to the June 2018 acquisition of and merger with Time Warner and/or (B) shares purchased between October 22, 2016 and October 24, 2018
Lead Plaintiff Deadline: May 31, 2019

AT&T Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) AT&T had substantially increased prices, while at the same time discontinuing promotional discounts for its DirecTV Now service; (ii) as a result, DirecTV Now subscribers were leaving (i.e., not renewing) as soon as their promotional discount periods expired, while at the same time new potential DirecTV Now customers were unwilling to pay the higher prices and therefore not subscribing at all; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Get additional information about the T lawsuit: http://www.kleinstocklaw.com/pslra-1/att-inc-loss-submission-form?wire=3

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
Class Period: November 4, 2015 to February 11, 2019
Lead Plaintiff Deadline: April 26, 2019

The complaint alleges that throughout the class period Vanda Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; (4) Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration; and (5) as a result, defendants’ statements about Vanda’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the VNDA lawsuit: http://www.kleinstocklaw.com/pslra-1/vanda-pharmaceuticals-inc-loss-submission-form?wire=3

U.S. Xpress Enterprises, Inc. (NYSE: USX)
Class Period: Purchasers of common stock pursuant/and or traceable to the initial public offering completed in June 2018
Lead Plaintiff Deadline: May 10, 2019

The complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress’s dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization, driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress’s dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress’s OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress’s insurance claim expense was understated; and (4) U.S. Xpress’s cost per mile for driver wages and independent contractors was exceeding the Company’s internal expectations.

Get additional information about the USX lawsuit: http://www.kleinstocklaw.com/pslra-1/u-s-xpress-enterprises-inc-loss-submission-form?wire=3

BrightView Holdings, Inc. (NYSE: BV)
Class Period: Purchasers of common stock pursuant to the IPO completed around July 2, 2018
Lead Plaintiff Deadline: June 14, 2019

The  complaint alleges that the defendants made materially false and/or misleading statements in the Offering Documents relating to the IPO, including omitting or failing to disclose that: (i) a material portion of BrightView’s contracts were underperforming and/or represented undesirable costs to the Company; (ii) as a result of the foregoing, BrightView would implement a “managed exit” strategy to end its low margin and non-profitable contracts with customers; (iii) this “managed exit” strategy would negatively impact BrightView’s future revenue throughout 2018, and would continue to do so well into fiscal year 2019; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.

Get additional information about the BV lawsuit: http://www.kleinstocklaw.com/pslra-1/brightview-holdings-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com